Next Article in Journal
In Vitro Evaluation of the Efficient Passage of PLGA-Formulated Trastuzumab for Nose-to-Brain Delivery
Next Article in Special Issue
The Development of a Multilayer Transdermal Patch Platform Based on Electrospun Nanofibers for the Delivery of Caffeine
Previous Article in Journal
Curcumin-Induced Apoptotic Cell Death in Human Glioma Cells Is Enhanced by Clusterin Deficiency
Previous Article in Special Issue
Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid–Rifampicin Combination Using the Self-Emulsification Mechanism †

1
Centre of Excellence for Pharmaceutical Sciences (PharmacenTM), Building G16, Faculty of Health Sciences, North-West University, Potchefstroom 2520, South Africa
2
Rural Health Research Institute, Charles Sturt University, Orange, NSW 2800, Australia
*
Author to whom correspondence should be addressed.
This paper is an extended version of our unpublished conference paper: Van Deventer, M.; Haynes, R.; Brits, M.; Viljoen, J. Formulation of a self-emulsifying drug delivery system containing a fixed-dose rifampicin-isoniazid combination. In Proceedings of the FIP World Conference, Cape Town, South Africa, 1–4 September 2024.
Pharmaceutics 2025, 17(6), 680; https://doi.org/10.3390/pharmaceutics17060680
Submission received: 24 March 2025 / Revised: 19 May 2025 / Accepted: 20 May 2025 / Published: 22 May 2025
(This article belongs to the Special Issue Dermal and Transdermal Drug Delivery Systems)

Abstract

Background: Tuberculosis remains a significant global health issue, and the rise of drug-resistant strains is becoming increasingly concerning. Currently, treatment options are limited to systemic regimens; however, developing topical drug delivery systems could offer advantages for treating cutaneous tuberculosis (CTB) when applied directly to the lesions. We developed topical emulsions using the self-emulsification mechanism that combine fixed doses of isoniazid (INH) and rifampicin (RIF) using a quality-by-design approach. Methods: Preformulation studies pertaining to drug solubility in various solvents, the construction of pseudoternary diagrams to identify self-emulsification regions for each tested excipient combination, and the preparation of checkpoint formulations were conducted and visually examined. Formulations displaying no physical instabilities were subsequently exposed to characterization experiments, including droplet size determination, zeta potential, size distribution, viscosity, pH, self-emulsification, cloud point, robustness to dilution, and thermodynamic stability assessment. Three selected formulations were consequently subjected to membrane release experiments, followed by skin diffusion studies, and INH and RIF stability in these emulsions was determined, because these drugs have a known interaction. Conclusions: While incorporating essential oils in a topical formulation improved RIF solubility, it also resulted in several instabilities. RIF exhibited greater susceptibility to degradation under higher temperatures and lower pH conditions. However, drug release from all formulations tested was confirmed. Notably, olive oil microemulsions demonstrated the most favorable characteristics for dermal drug delivery; nonetheless, drug diffusion into and through the skin (which was not desired) could not be quantified. Despite these challenges, the findings indicate that topical drug delivery systems using the self-emulsification process can facilitate the direct treatment of CTB.
Keywords: cutaneous tuberculosis (CTB); isoniazid (INH); rifampicin (RIF); self-emulsifying mechanism; topical delivery; pseudoternary phase diagrams cutaneous tuberculosis (CTB); isoniazid (INH); rifampicin (RIF); self-emulsifying mechanism; topical delivery; pseudoternary phase diagrams

Share and Cite

MDPI and ACS Style

van Deventer, M.; Haynes, R.K.; Brits, M.; Viljoen, J.M. Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid–Rifampicin Combination Using the Self-Emulsification Mechanism. Pharmaceutics 2025, 17, 680. https://doi.org/10.3390/pharmaceutics17060680

AMA Style

van Deventer M, Haynes RK, Brits M, Viljoen JM. Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid–Rifampicin Combination Using the Self-Emulsification Mechanism. Pharmaceutics. 2025; 17(6):680. https://doi.org/10.3390/pharmaceutics17060680

Chicago/Turabian Style

van Deventer, Melissa, Richard K. Haynes, Marius Brits, and Joe M. Viljoen. 2025. "Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid–Rifampicin Combination Using the Self-Emulsification Mechanism" Pharmaceutics 17, no. 6: 680. https://doi.org/10.3390/pharmaceutics17060680

APA Style

van Deventer, M., Haynes, R. K., Brits, M., & Viljoen, J. M. (2025). Formulation of Topical Drug Delivery Systems Containing a Fixed-Dose Isoniazid–Rifampicin Combination Using the Self-Emulsification Mechanism. Pharmaceutics, 17(6), 680. https://doi.org/10.3390/pharmaceutics17060680

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop